MENU
May 14, 2020

OncomineWorld: A Virtual NGS Education Meeting


Whether your laboratory currently utilizes next-generation sequencing (NGS), or you are curious to learn more, access this on-demand event to hear about the latest developments in cancer genomic profiling—from research to diagnostics.

Even in these difficult times, research, learning, and knowledge exchange in precision oncology research must continue, just as routine patient testing and treatment must.

In this virtual NGS education meeting, you will have the opportunity to:

  • Earn continuing education (CE) credits by listening to 12 educational talks from leading NGS users on topics such as comprehensive genomic profiling (CGP), the future of precision oncology biomarkers testing in the routine clinical space, personal experiences with different NGS products and solutions, and much more.
  • Explore the NGS Oncology Application Hall and its many specialty booth-labs including immuno-oncology research, emerging NSCLC biomarkers, liquid biopsy, PIK3Ca research testing, and hemato-oncology research.
  • Visit our virtual lab to experience the new world of easy and fast NGS - the Ion Torrent Genexus System - and become familiar with our well-proven workhorse, the Ion Torrent GeneStudio system, with its many applications.
  • Visit the Precision Oncology Hall to access videos, posters and more on the future potential of NGS in the clinic.
  • See the latest research by Thermo Fisher Scientific in the Poster Hall.

We hope you will enjoy and benefit from this meeting. We are open to any questions or feedback before, during, and after the live event.

Sincerely,

Your Thermo Fisher Scientific Oncology NGS team

For Research Use Only. Not for use in diagnostic procedures.


Speakers

Show Resources
You May Also Like
SEP 23, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 23, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Please join us at the 9th Annual Fluidigm Mass Cytometry Virtual Summit This yearly international meeting of the mass cytometry community is designed for new and experienced users, as well a...
SEP 29, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 29, 2020 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Due to the fact that many large events and scientific conferences have been cancelled, we want to provide you with an outlet to present your research and learn from others in our community....
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 12, 2020 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Ten years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2020 Clinical Diagnostics and Research Virtual Event will again bring together clinicians,...
OCT 28, 2020 7:00 AM GMT, 12:30PM IST, 3:00PM SGT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
OCT 28, 2020 7:00 AM GMT, 12:30PM IST, 3:00PM SGT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Each step in a diagnostic test's journey-from raw material extraction to patient administration-can influence outcomes....
SEP 07, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
SEP 07, 2021 6:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
LabRoots is excited to bring academia and industry, research experts, virologists, microbiologists, healthcare professionals, and leading biomedical scientists under one roof at our 7 th Ann...
NOV 11, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
NOV 11, 2021 6:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Twelveyears ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2021 Clinical Diagnostics and Research Virtual Event will again bring together clinician...
Agenda
  • Haemato-Oncology Applications of BCR Immune Repertoire Sequencing
    MAY 14, 2020 7:05 PM EDT
    Haemato-Oncology Applications of BCR Immune Repertoire Sequencing
    Timothy Looney, PhD
    Associate Director, Bioinformatics; Clinical Next-Generation Sequencing
  • Genomic profiling of prostate cancer cells from urine using Oncomine Pan Cancer Cell Free Assay
    MAY 14, 2020 6:40 PM EDT
    Genomic profiling of prostate cancer cells from urine using Oncomine Pan Cancer Cell Free Assay
    Jane Bayani, PhD
    Principal Research Scientist, Ontario Institute for Cancer Research
  • Experience with Oncomine Myeloid Research Assay
    MAY 14, 2020 6:05 PM EDT
    Experience with Oncomine Myeloid Research Assay
    Xia Li, PhD, FACMG, DABMGG
    Scientific Medical Director, Sonora Quest Laboratories, Tempe, US
  • First experience with the Ion Torrent Genexus Workflow
    MAY 14, 2020 5:40 PM EDT
    First experience with the Ion Torrent Genexus Workflow
    Kojo Elenitoba-Johnson, MD
    Director, Center for Personalized Diagnostics Director, Division of Precision and Computational Diagnostics, University of Pennsylvania Perelman School of Medicine
  • Molecular Profiling for Treatment Guidance of Hematologic Malignancies by Next Generation Sequencing
    MAY 14, 2020 5:00 PM EDT
    Molecular Profiling for Treatment Guidance of Hematologic Malignancies by Next Generation Sequencing
    Xia Li, PhD, FACMG, DABMGG
    Scientific Medical Director, Sonora Quest Laboratories, Tempe, US
  • Lymphoid and Myeloid NGS Molecular Characterization - Assessing the Journey to Answers
    MAY 14, 2020 4:40 PM CEST
    Lymphoid and Myeloid NGS Molecular Characterization - Assessing the Journey to Answers
    Marianne Grantham
    Clinical Scientist, Head of Cytogenetics and Molecular Haematology, Barts Health NHS Trust The Royal London Hospital
  • Advantages and Challenges of Broad Molecular Profiling
    MAY 14, 2020 4:15 PM CEST
    Advantages and Challenges of Broad Molecular Profiling
    Ilaria Alborelli, PhD
    Scientific Operations Manager, Molecular Assay Development Unit Institute of Medical Genetics and Pathology, University Hospital of Basel - Switzerland
  • Genexus - A Major Step Forward in Diagnostic NGS
    MAY 14, 2020 3:30 PM CEST
    Genexus - A Major Step Forward in Diagnostic NGS
    Michael Hummel, PhD
    Head of Molecular Pathology, Charité - Universitätsmedizin Berlin, Institute of Pathology, Germany
  • Analysis of Solid Tumor Genomic Landscape in Liquid Biopsy
    MAY 14, 2020 3:00 PM CEST
    Analysis of Solid Tumor Genomic Landscape in Liquid Biopsy
    Nicola Normanno, MD
    National Cancer Institute Fondazione G. Pascale, Naples
  • Emerging Biomarkers in Non-small Cell Lung Cancer
    MAY 14, 2020 3:00 PM CEST
    Emerging Biomarkers in Non-small Cell Lung Cancer
    Luca Quagliata, PhD
    Global Head of Medical Affairs, Clinical NGS and Oncology Division, Thermo Fisher Scientific
    Continuing Education: Florida CE | P.A.C.E. CE
  • Evaluation of Genexus Integrated Sequencer that Automates Specimen-to-report for Cancer Genomic Profiling within a Day Using Liquid Biopsy
    MAY 14, 2020 2:40 PM SGT
    Evaluation of Genexus Integrated Sequencer that Automates Specimen-to-report for Cancer Genomic Profiling within a Day Using Liquid Biopsy
    Siew-Kee (Amanda) Low, PhD
    Group Leader for Cancer Neoantigen Vaccine Development Group, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research (JFCR)
  • First Experience from New World of Easy NGS - Ion Torrent Genexus Workflow
    MAY 14, 2020 2:15 PM SGT
    First Experience from New World of Easy NGS - Ion Torrent Genexus Workflow
    Philip Jermann, PhD
    Director of the Molecular Assay Development Unit, Institute of Pathology and Medical Genetics of Basel
  • NATA Accreditation of Next Generation Sequencing for CDx Testing
    MAY 14, 2020 1:25 PM SGT
    NATA Accreditation of Next Generation Sequencing for CDx Testing
    Luke Hesson, PhD, FFScRCPA
    Laboratory Director, KCCG Sequencing Facility & Cancer Diagnostics​, Australia
    Continuing Education: Florida CE | P.A.C.E. CE
  • Test Validation in Medical Laboratories: the Australian Perspective
    MAY 14, 2020 1:25 PM SGT
    Test Validation in Medical Laboratories: the Australian Perspective
    Luke Hesson, PhD, FFScRCPA
    Laboratory Director, KCCG Sequencing Facility & Cancer Diagnostics​, Australia
  • Implementation of Multigene Testing for 1st line NSCLC - A Malaysian initiative
    MAY 14, 2020 1:00 PM SGT
    Implementation of Multigene Testing for 1st line NSCLC - A Malaysian initiative
    Pathmanathan Rajadurai, MBBS, FRCPA, FRCPath
    Senior Consultant Pathologist and Laboratory Director
  • Emerging Biomarkers
    MAY 13, 2020 5:20 PM EDT
    Emerging Biomarkers
    Carl Morrison, PhD
    Senior Vice President of Scientific Development and Integrative Medicine, Roswell Park Comprehensive Cancer Center
    Continuing Education: Florida CE | P.A.C.E. CE
  • Part 1: NGS in Precision Oncology - General Education
  • Emerging Biomarkers
    MAY 13, 2020 5:20 PM EDT
    Emerging Biomarkers
    Carl Morrison, PhD
    Senior Vice President of Scientific Development and Integrative Medicine, Roswell Park Comprehensive Cancer Center
    Continuing Education: Florida CE | P.A.C.E. CE
  • NATA Accreditation of Next Generation Sequencing for CDx Testing
    MAY 14, 2020 1:25 PM SGT
    NATA Accreditation of Next Generation Sequencing for CDx Testing
    Luke Hesson, PhD, FFScRCPA
    Laboratory Director, KCCG Sequencing Facility & Cancer Diagnostics​, Australia
    Continuing Education: Florida CE | P.A.C.E. CE
  • Live Session 1
    • Part 1: NGS in Precision Oncology - General Education
    • Implementation of Multigene Testing for 1st line NSCLC - A Malaysian initiative
      MAY 14, 2020 1:00 PM SGT
      Implementation of Multigene Testing for 1st line NSCLC - A Malaysian initiative
      Pathmanathan Rajadurai, MBBS, FRCPA, FRCPath
      Senior Consultant Pathologist and Laboratory Director
    • Test Validation in Medical Laboratories: the Australian Perspective
      MAY 14, 2020 1:25 PM SGT
      Test Validation in Medical Laboratories: the Australian Perspective
      Luke Hesson, PhD, FFScRCPA
      Laboratory Director, KCCG Sequencing Facility & Cancer Diagnostics​, Australia
    • Part 2: Experiences with Oncomine Solutions for Clinical Research
    • First Experience from New World of Easy NGS - Ion Torrent Genexus Workflow
      MAY 14, 2020 2:15 PM SGT
      First Experience from New World of Easy NGS - Ion Torrent Genexus Workflow
      Philip Jermann, PhD
      Director of the Molecular Assay Development Unit, Institute of Pathology and Medical Genetics of Basel
    • Evaluation of Genexus Integrated Sequencer that Automates Specimen-to-report for Cancer Genomic Profiling within a Day Using Liquid Biopsy
      MAY 14, 2020 2:40 PM SGT
      Evaluation of Genexus Integrated Sequencer that Automates Specimen-to-report for Cancer Genomic Profiling within a Day Using Liquid Biopsy
      Siew-Kee (Amanda) Low, PhD
      Group Leader for Cancer Neoantigen Vaccine Development Group, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research (JFCR)
  • Live Session 2
    • Part 1: NGS IN PRECISION ONCOLOGY - GENERAL EDUCATION
    • Analysis of Solid Tumor Genomic Landscape in Liquid Biopsy
      MAY 14, 2020 3:00 PM CEST
      Analysis of Solid Tumor Genomic Landscape in Liquid Biopsy
      Nicola Normanno, MD
      National Cancer Institute Fondazione G. Pascale, Naples
    • Part 1: NGS in Precision Oncology - General Education
    • Emerging Biomarkers in Non-small Cell Lung Cancer
      MAY 14, 2020 3:00 PM CEST
      Emerging Biomarkers in Non-small Cell Lung Cancer
      Luca Quagliata, PhD
      Global Head of Medical Affairs, Clinical NGS and Oncology Division, Thermo Fisher Scientific
      Continuing Education: Florida CE | P.A.C.E. CE
    • Part 2: Experiences with Oncomine Solutions for Clinical Research
    • Genexus - A Major Step Forward in Diagnostic NGS
      MAY 14, 2020 3:30 PM CEST
      Genexus - A Major Step Forward in Diagnostic NGS
      Michael Hummel, PhD
      Head of Molecular Pathology, Charité - Universitätsmedizin Berlin, Institute of Pathology, Germany
    • Advantages and Challenges of Broad Molecular Profiling
      MAY 14, 2020 4:15 PM CEST
      Advantages and Challenges of Broad Molecular Profiling
      Ilaria Alborelli, PhD
      Scientific Operations Manager, Molecular Assay Development Unit Institute of Medical Genetics and Pathology, University Hospital of Basel - Switzerland
    • Lymphoid and Myeloid NGS Molecular Characterization - Assessing the Journey to Answers
      MAY 14, 2020 4:40 PM CEST
      Lymphoid and Myeloid NGS Molecular Characterization - Assessing the Journey to Answers
      Marianne Grantham
      Clinical Scientist, Head of Cytogenetics and Molecular Haematology, Barts Health NHS Trust The Royal London Hospital
  • Live Session 3
    • Part 1: NGS in Precision Oncology - General Education
    • Molecular Profiling for Treatment Guidance of Hematologic Malignancies by Next Generation Sequencing
      MAY 14, 2020 5:00 PM EDT
      Molecular Profiling for Treatment Guidance of Hematologic Malignancies by Next Generation Sequencing
      Xia Li, PhD, FACMG, DABMGG
      Scientific Medical Director, Sonora Quest Laboratories, Tempe, US
    • Part 2: Experiences with Oncomine Solutions for Clinical Research
    • First experience with the Ion Torrent Genexus Workflow
      MAY 14, 2020 5:40 PM EDT
      First experience with the Ion Torrent Genexus Workflow
      Kojo Elenitoba-Johnson, MD
      Director, Center for Personalized Diagnostics Director, Division of Precision and Computational Diagnostics, University of Pennsylvania Perelman School of Medicine
    • Experience with Oncomine Myeloid Research Assay
      MAY 14, 2020 6:05 PM EDT
      Experience with Oncomine Myeloid Research Assay
      Xia Li, PhD, FACMG, DABMGG
      Scientific Medical Director, Sonora Quest Laboratories, Tempe, US
    • Genomic profiling of prostate cancer cells from urine using Oncomine Pan Cancer Cell Free Assay
      MAY 14, 2020 6:40 PM EDT
      Genomic profiling of prostate cancer cells from urine using Oncomine Pan Cancer Cell Free Assay
      Jane Bayani, PhD
      Principal Research Scientist, Ontario Institute for Cancer Research
    • Haemato-Oncology Applications of BCR Immune Repertoire Sequencing
      MAY 14, 2020 7:05 PM EDT
      Haemato-Oncology Applications of BCR Immune Repertoire Sequencing
      Timothy Looney, PhD
      Associate Director, Bioinformatics; Clinical Next-Generation Sequencing
Speakers

  • MODERATOR: Luca Quagliata, PhD
    Global Head of Medical Affairs, Clinical NGS and Oncology Division, Thermo Fisher Scientific
  • Ilaria Alborelli, PhD
    Scientific Operations Manager, Molecular Assay Development Unit Institute of Medical Genetics and Pathology, University Hospital of Basel - Switzerland
    Biography
      Dr. Alborelli received her Master's Degree in Molecular Biology at the University of Milan in 2011 and completed her PhD in 2016 in the field of Genetics at the Biozentrum of Basel, Switzerland, where she studied signaling pathway reception using CRISPR/Cas9-based genome engineering and acute protein manipulation. She then continued this project as a post-doctoral fellow working on engineering single-chain antibodies (nanobodies) for in vivo protein manipulation. Since 2017 she joined the Institute of Medical Genetics and Pathology in Basel as scientific project manager of the Molecular Assay Development Unit, working on the development and evaluation of novel molecular diagnostics assays. Her main focus is the establishment of tools for biomarkers assessment in the field of immunotherapy and the clinical validation of molecular assays for tissue and liquid biopsy.
    • Jane Bayani, PhD
      Principal Research Scientist, Ontario Institute for Cancer Research
      Biography
        Dr. Bayani is a Principal Research Scientist at the Ontario Institute for Cancer Research in the Department of Diagnostic Development. She obtained her PhD at the University of Toronto in the Department of Laboratory Medicine and Pathobiology. She has an extensive background in molecular pathology and molecular cytogenetics and now leads a number of the genomic translational research projects as part of the senior scientific team in Diagnostic Development. Her focus is on precision medicine approaches for prognostic and predictive biomarkers in early hormone receptor positive breast cancers and in early prostate cancer.
      • Kojo Elenitoba-Johnson, MD
        Director, Center for Personalized Diagnostics Director, Division of Precision and Computational Diagnostics, University of Pennsylvania Perelman School of Medicine
        Biography
          KOJO S. J. ELENITOBA-JOHNSON, MD is the Peter C. Nowell, MD, Professor and Founding Director of the Penn Center for Personalized Diagnostics, and Founding Director of the Division of Precision and Computational Diagnostics at the Perelman School of Medicine at the University of Pennsylvania. Dr. Elenitoba-Johnson earned his medical degree from the College of Medicine, University of Lagos in Lagos, Nigeria. He has board certification in AP/CP, hematopathology and molecular genetic pathology. His research focuses on molecular pathogenesis and precision diagnostics with particular emphasis on identification of therapeutic targets for hematopoietic neoplasia. Elenitoba-Johnson has been recognized with numerous awards, including the Ramzi Cotran Young Investigator Award from the United States and Canadian Academy of Pathology in 2006 and the Outstanding Investigator Award given by the American Society for Investigative Pathology (2012). In 2018, he served as President of the Association of Molecular Pathologists (AMP). He has authored more than 170 peer-reviewed research publications and has contributed over 20 chapters in professional text-books.
        • Marianne Grantham
          Clinical Scientist, Head of Cytogenetics and Molecular Haematology, Barts Health NHS Trust The Royal London Hospital
          Biography
            Marianne Grantham is a Clinical Scientist and Head of the Cytogenetics and Molecular Haematology Department at Barts Health NHS Trust in London. After graduating from the University of Birmingham with a Bachelor's degree in Genetics in 1996, she joined the NHS to train as a Clinical Cytogeneticist. Early on in her career she discovered her passion lay in the genomics of haematological malignancies and its integration into clinical care. Marianne has worked in several large teaching hospitals across the globe including Great Ormond Street Hospital for Sick Children and St Vincent's Hospital in Sydney Australia and has worked at Barts Health since 2003. Marianne has a specialist interest in training and people development including making genomics accessible for all healthcare staff and is an honorary lecturer at Queen Mary, University of London. In 2019, Marianne was appointed as the Lead Scientist for Haematological Malignancies for the North Thames Genomic Laboratory Hub.
          • Luke Hesson, PhD, FFScRCPA
            Laboratory Director, KCCG Sequencing Facility & Cancer Diagnostics​, Australia
            Biography
              Associate Professor Luke Hesson is Director of a medical testing laboratory at the Garvan Institute of Medical Research and also researches genetic and epigenetic variants that contribute to the development of cancer and the role these play in the clinical management of patients, including their diagnosis and response to therapy. Luke is a Fellow of the Faculty of Science of the Royal College of Pathologists of Australasia and Editor of the Springer Nature textbook Clinical Epigenetics.
            • Michael Hummel, PhD
              Head of Molecular Pathology, Charité - Universitätsmedizin Berlin, Institute of Pathology, Germany
              Biography
                Prof. Dr Michael Hummel is head of the molecular diagnostics at the Institute of Pathology (Charité, Berlin) and a longstanding researcher with a scientific topic for molecular mechanisms in malignant lymphoma (more than 350 high ranking publications). Molecular diagnostics at Charité covers a broad spectrum of assays ranging from simple PCRs for the detection of viral and bacterial infections, complex PCRs for B- and T-cell clonality, RT-PCR based gene expression for breast cancer, FISH for chromosomal alterations and targeted NGS (started in June 2014) for mutation analysis in cancer tissues and liquid biopsies. The samples of many thousands of patients are being analyzed in our molecular lab every year. For the NGS assays, we are running the S5XL/ION Chef workflow as well as Illumina and QIAGEN platforms. Since March 2018, Charité is member of the Thermo Fisher Center of Excellence Program (COEP). In addition to the above described activities Michael Hummel is the director of the central biobank at the Charité and the Berlin Institute of Health (BIH). Furthermore he is Director of the German Biobank Node and Coordinator of the German Biobank Alliance. In this function he is responsible for the coordination and harmonization of the national biobanking activities and for the representation of the German biobank community at the European level in the frame of the biobanking infrastructure BBMRI-ERIC.
              • Philip Jermann, PhD
                Director of the Molecular Assay Development Unit, Institute of Pathology and Medical Genetics of Basel
                Biography
                  Dr. Jermann received his Master's Degree in Biochemistry at the ETH in Zurich in 2009 and did his PhD studies in the field of epigenetics at the Friedrich Miescher Institute in Basel, Switzerland, where he studied the function of histone- and DNA modifications in embryonic stem cells. He then worked as an expert for next-generation sequencing where he helped establish and support several NGS-based diagnostic laboratories throughout Switzerland and the EMEA region. In 2017, Dr. Jermann joined the Institute of Medical Genetics and Pathology in Basel where he and his team are responsible for the development and evaluation of novel molecular diagnostics assays.
                • Xia Li, PhD, FACMG, DABMGG
                  Scientific Medical Director, Sonora Quest Laboratories, Tempe, US
                  Biography
                    Dr. Xia Li is the Scientific Medical Director of Genetics/Genomics Division at Sonora Quest Laboratories and Associate Professor of Pathology Department at University of Arizona. She oversees the operation of the laboratory and participates in the teaching and training of medical students and residents. Dr. Li has been working in the field of Genetics/Genomics diagnostics since 2008, and was certified in both Molecular and Cytogenetics through ABMGG. Before joining Sonora Quest Laboratories in 2016, Dr. Li was the Associate Director of Cytogenetics Laboratory at Cincinnati Children's Hospital from 2013 to 2016, and Associate Director of Cytogenetics Laboratory at AmeriPath Northeast from 2010-2013. She has extensive experience in cancer diagnostics using karyotyping, FISH, PCR, microarray and NGS technologies. She has published over 50 peer-reviewed articles and owns 2 patents. Dr. Li enjoys dancing, hiking and sewing. She has sewed over 200 cloth masks for colleagues and friends during this pandemic.
                  • Timothy Looney, PhD
                    Associate Director, Bioinformatics; Clinical Next-Generation Sequencing
                    Biography
                      Dr. Looney is an accomplished computational biologist and immunologist with expertise in methods and applications of B and T cell receptor sequencing, including biomarker discovery and assay development. He is an Associate Director of Bioinformatics and the Informatics Lead for Immune Repertoire Sequencing within the Clinical Sequencing Division at Thermo Fisher Scientific. Dr. Looney's interest focuses on biomarker and basic immunology applications of immune repertoire analysis. He received a PhD in Genetics from the University of Chicago and performed his post-doctoral work at Stanford University, where he developed methods for immune repertoire sequencing.
                    • Siew-Kee (Amanda) Low, PhD
                      Group Leader for Cancer Neoantigen Vaccine Development Group, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research (JFCR)
                      Biography
                        2008-2011: Doctor of Philosophy (Ph.D) in Medical Genomics, The University of Tokyo, Japan. 2011-2012: JSPS Postdoctoral fellows at Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo and visiting researcher for the Division of Genetics, National Cancer Center Research Institute, Japan. 2012-2014: Research Scientist at Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, The Institute of Physical and Chemical Research (RIKEN), Japan. 2015-2016: Lecturer at Faculty of Pharmacy, University of Sydney, Australia. 2017-Current: Group leader for Cancer Neoantigen Vaccine Development Group, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research (JFCR). Siew-Kee (Amanda) Low has been working extensively in genomic research that expands from cancer genomics, pharmacogenomics and various genomic studies for complex diseases. During her Ph.D. and postdoctoral fellows, she has performed comprehensive genomic analysis by utilizing large-scale genome-wide association studies (GWAS) and whole genome/exome studies to identify genetic variations associated with various complex diseases and pharmacogenomics studies. She is also the lead biostatistician representing Biobank Japan participating various international consortium. She has published in top-notch journals such as Nature Genetics, PNAS, Human Molecular genetics and etc. Currently, she is establishing the liquid biopsy system for cancer suivellance and monitoring in JFCR. As part of the Japan national project "Innovative AI hospital system", she is one of the leaders to standardize and implement liquid biopsy in the medical system in Japan.
                      • Nicola Normanno, MD
                        National Cancer Institute Fondazione G. Pascale, Naples
                        Biography
                          Dr. Normanno, MD earned his Medical Doctor Degree in 1988 at the Medical School, University of Naples (Italy) Federico II. After a residency in Oncology at the Oncology Department of the same university, in 1991 he achieved the specialisation in Medical Oncology, and in 2001 in Haematology. Between 1990 and 1993, Dr Normanno did a postdoctoral fellowship at the Tumor Growth Factor Section, Laboratory of Tumour Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. After being senior Investigator and later Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Director of the Cell Biology and Biotherapy-Unit at the same Hospital, and since 2006 also Director of the Translational Research Department. Since 1993 Dr Normanno's area of research has been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumors; the identification of markers of response or resistance to anti-EGFR agents; the implementation of precision medicine in the path of care of cancer patients. Dr Normanno is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR), the Italian Association of Medical Oncology (AIOM), and the Italian Cancer Society (SIC). He is from 2018 President of the International Quality Network for Pathology (IQN Path) and from 2020 President of the Italian Cancer Society (SIC). Dr Normanno is a reviewer for several peer-reviewed journals including Annals of Oncology, Clinical Cancer Research, International Journal of Cancer, European Journal of Cancer, British Journal of Cancer, Nature Communications. He is also Editor of Exploration of Targeted Anti-tumor Therapy and Associate Editor of BMC Cancer and Gene. Dr Normanno is the author of over 200 papers published in peer-reviewed journals with an H Index of 68.
                        • Pathmanathan Rajadurai, MBBS, FRCPA, FRCPath
                          Senior Consultant Pathologist and Laboratory Director
                          Biography
                            Dr. Pathmanathan is Senior Consultant Pathologist and Laboratory Director in the Subang Jaya by Medical Centre, Subang Jaya. He is also currently Professor of Anatomical Pathology in the Tan Sri Jeffrey Cheah School of Medicine, Monash University, Adjunct Professor of Pathology in Manipal University (Manipal campus) and is Visting Professor of Pathology in the University of Malaya Medical Centre. He is an established researcher with more than 230 scientific publications in international and peer-reviewed journals and serves on the Editorial Board of "Pathology". He serves as advisor and consultant for multinational pathology diagnostics companies as well as pharmaceutical companies. His current research areas are in the molecular pathology of cancers, telepathology and digital imaging.
                          C.E. Credits

                          The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                          Help

                          General LabRoots Questions

                          email support@labroots.com  

                          Virtual Events and Webinars

                          Supported Configurations

                          • Operating System Internet Explorer Firefox Chrome Safari
                            Vista IE8+ FF10+ Chrome15+
                            Windows 7 IE8+ FF10+ Chrome15+
                            Windows 8 IE10 FF10+ Chrome15+
                            Mac OS X   FF10+ Chrome15+ Safari5.1+
                          • Cookie settings: session cookies enabled
                          • Browser configuration must have JavaScript enabled
                          • Adobe Flash player 10.2 or later

                          To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                          Internet Connection

                          • A minimum of 100Kbps is recommended for audio-only events
                          • A minimum of 300Kbps is recommended for speaker on-video events

                          Computer Equipment

                          • Screen Resolution: Minimum 1024x768
                          • Video Card: 65,000 colors minimum
                          • Sound card and speakers (or headphones) for hearing webcast in full format
                          • Audio Card: 16-bit minimum
                          • RAM: 512MB of free RAM

                          Firewall Protocol

                          • HTTP on port 80 or HTTPS on port 443
                          • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                          • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                          Work-At-Home Attendees

                          • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                          For A Seamless Experience

                          When using a mobile device, FREE Mobile Apps are available:

                          - For viewing Webinars:

                          - For viewing Virtual Events

                          Attendee Guide

                          • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                          Virtual Event and Webinar Support:

                          Continuing Education (CME/CE) Support

                          Loading Comments...
                          Show Resources
                          Attendees
                          • See more